Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Rosaria Di Lorenzo, Paola Ferri, Michela Cameli, Sergio Rovesti & Chiara Piemonte. (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment 15, pages 183-198.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Ilaria Cuomo, Georgios D Kotzalidis, Simone de Persis, Daria Piacentino, Filippo Perrini, Emanuela Amici & Sergio De Filippis. (2018) Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatric Disease and Treatment 14, pages 1645-1656.
Read now
Read now
Solomon Nuhoho, Abdallah Saad, Goretti Saumell, Daniel Ribes & Antoine C. El Khoury. (2018) Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates. Current Medical Research and Opinion 34:4, pages 601-611.
Read now
Read now
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Thomas R. Einarson, Susana Maia-Lopes, Pushpendra Goswami, Basil G. Bereza & Kristel Van Impe. (2016) Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. Journal of Medical Economics 19:9, pages 913-921.
Read now
Read now
Articles from other publishers (8)
Grace Hsin-Min WangMikael SvenssonHui ShaoScott Martin VouriHaesuk Park. (2023) Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia. Journal of Managed Care & Specialty Pharmacy 29:8, pages 884-895.
Crossref
Crossref
Rosaria Di Lorenzo, Anita Iorio, Margherita Pinelli, Federica Maria Magarini, Mattia Marchi, Andrea Sacchetti, Chiara Calogero, Gian Galeazzi, Paola Ferri, Sergio Rovesti & Alessandro Minarini. (2022) Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. Neuropsychiatric Disease and Treatment Volume 18, pages 829-846.
Crossref
Crossref
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu & Hongchao Li. (2021) A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. Frontiers in Public Health 9.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, David Aceituno & Sarah Byford. (2020) Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. PLOS ONE 15:7, pages e0234996.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Crossref
John R. Tomko, Nadeem Ahmed, Cynthia KuntzJustine Zick. (2016) A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis. Hospital Pharmacy 51:10, pages 834-840.
Crossref
Crossref